AMPH
BEARISH
$18.18
Live
Amphastar Pharmaceuticals, Inc. · NASDAQ
Target $29.0
(+59.5%)
$17.03
52W Range
$31.26
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$835.41M
P/E
8.96
ROE
12.9%
Profit margin
13.6%
Debt/Equity
0.83
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
AMPH exhibits strong deterministic health with a Piotroski F-Score of 7/9, indicating solid operational efficiency and financial stability, though the absence of an Altman Z-Score raises concern about default risk. The stock trades at a discount to its Graham Number ($28.09) and intrinsic value ($14.21), suggesting undervaluation on a defensive basis. However, this is overshadowed by deteriorating fundamentals: negative revenue and earnings growth (YoY -1.8% and -31.0%), declining quarterly earnings, and a significant 36.4% drop in price over the past month. Insider selling activity further undermines confidence, with $0.95M in sales over six months despite no buy activity.
Key Strengths
Piotroski F-Score of 7/9 indicates strong financial health and operational efficiency
Graham Number of $28.09 suggests defensive undervaluation relative to intrinsic safety margin
High gross margin (49.46%) and operating margin (19.45%) reflect strong pricing power and cost control
Low debt-to-equity ratio (0.83) and high current ratio (4.02) signal strong liquidity and low leverage risk
Analyst consensus is 'buy' with a target price of $29.00, implying upside potential
Key Risks
Negative year-over-year earnings growth (-31.0%) and revenue decline (-1.8%) indicate deteriorating business momentum
Recent insider selling of $0.95M over six months signals potential lack of confidence from management
Stock has declined 36.4% in one month and 51.1% over three years, reflecting prolonged underperformance
No dividend and zero payout ratio eliminate income appeal and signal reinvestment focus without clear growth
Technical trend is bearish (0/100), confirming negative momentum and weak price action
AI Fair Value Estimate
Based on comprehensive analysis
$14.21
-21.8% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
50
Moderate
72
35
68
75
0
AI Verdict
neutral-to-bearish
Key drivers: Strong Piotroski F-Score and liquidity metrics, Significant earnings and revenue decline, Negative technical momentum and insider selling, Undervaluation on Graham basis but not supported by growth, Lack of Altman Z-Score introduces uncertainty
Confidence
85%
Value
72/100
Ref P/E, PEG, Graham Number
Positives
- Current price ($18.18) is below Graham Number ($28.09)
- Price/Book (1.05) and P/E (8.96) are low relative to sector
- Intrinsic value estimate ($14.21) suggests downside protection
Watchpoints
- P/E of 8.96 is misleading due to negative earnings growth
- No PEG ratio available, limiting growth-adjusted valuation
- Stock has underperformed for years despite low valuation
Future
35/100
Ref Growth rates
Positives
- Analyst target price of $29.00 implies 60% upside
- Some recent quarters beat estimates (e.g., +32.2% surprise in 2024 Q1)
Watchpoints
- Negative YoY earnings growth (-31.0%) and Q/Q decline (-35.7%)
- Revenue growth is negative (-1.8%)
- Most recent EPS growth is -21.5% Q/Q
- No visible recovery in forward guidance
Past
68/100
Ref Historical trends
Positives
- Historical earnings surprises have been positive in many quarters (e.g., +82.5% in 2023 Q1)
- Consistent profitability with stable margins over time
- Piotroski F-Score of 7/9 reflects strong historical performance
Watchpoints
- Recent earnings trajectory shows clear deterioration
- Five of last six quarters show declining EPS
- 2026 Q1 missed estimates by 20.5%
Health
75/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 7/9 indicates strong financial health
- Low debt-to-equity (0.83) and high current ratio (4.02) suggest resilience
- Positive operating and gross margins
Watchpoints
- No Altman Z-Score available, which is a critical gap for distress risk assessment
- High cash levels not quantified, limiting full health evaluation
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100
- No income stream for investors
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$18.18
Analyst Target
$29.0
Upside/Downside
+59.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AMPH and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Primary
|
-5.1% | -51.1% | -30.7% | -35.2% | -36.4% | -6.0% |
|
TLRY
Tilray Brands, Inc.
Peer
|
-95.8% | -68.9% | +58.9% | -54.5% | +15.1% | +6.4% |
|
MNKD
MannKind Corporation
Peer
|
-36.3% | -32.0% | -40.8% | -46.3% | -1.1% | +6.6% |
|
SPRY
ARS Pharmaceuticals, Inc.
Peer
|
-78.3% | +19.2% | -45.0% | -18.6% | -1.4% | +1.6% |
|
TBPH
Theravance Biopharma, Inc.
Peer
|
-25.6% | +44.6% | +83.1% | +16.8% | +16.7% | +1.3% |
AMP
Amphastar Pharmaceuticals, Inc.
Primary
5Y
-5.1%
3Y
-51.1%
1Y
-30.7%
6M
-35.2%
1M
-36.4%
1W
-6.0%
TLR
Tilray Brands, Inc.
Peer
5Y
-95.8%
3Y
-68.9%
1Y
+58.9%
6M
-54.5%
1M
+15.1%
1W
+6.4%
MNK
MannKind Corporation
Peer
5Y
-36.3%
3Y
-32.0%
1Y
-40.8%
6M
-46.3%
1M
-1.1%
1W
+6.6%
SPR
ARS Pharmaceuticals, Inc.
Peer
5Y
-78.3%
3Y
+19.2%
1Y
-45.0%
6M
-18.6%
1M
-1.4%
1W
+1.6%
TBP
Theravance Biopharma, Inc.
Peer
5Y
-25.6%
3Y
+44.6%
1Y
+83.1%
6M
+16.8%
1M
+16.7%
1W
+1.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
8.96
Forward P/E
5.21
PEG Ratio
N/A
P/B Ratio
1.05
P/S Ratio
1.16
EV/Revenue
1.66
EV/EBITDA
5.44
Market Cap
$835.41M
Profitability
Profit margins and return metrics
Profit Margin
13.63%
Operating Margin
19.45%
Gross Margin
49.46%
ROE
12.9%
ROA
6.37%
Growth
Revenue and earnings growth rates
Revenue Growth
-1.8%
Earnings Growth
-31.0%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
-35.7%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.83
Moderate
Current Ratio
4.02
Strong
Quick Ratio
2.8
Excellent
Cash/Share
$6.23
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-02-26
$0.73
-20.5% surprise
2025-11-06
$0.93
+12.7% surprise
2025-08-07
$0.85
+14.6% surprise
Healthcare Sector Comparison
Comparing AMPH against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
8.96
This Stock
vs
75.44
Sector Avg
-88.1%
(Discount)
Return on Equity (ROE)
12.9%
This Stock
vs
-88.14%
Sector Avg
-114.6%
(Below Avg)
Profit Margin
13.63%
This Stock
vs
-16.28%
Sector Avg
-183.7%
(Weaker)
Debt to Equity
0.83
This Stock
vs
2.66
Sector Avg
-68.8%
(Less Debt)
Revenue Growth
-1.8%
This Stock
vs
124.04%
Sector Avg
-101.5%
(Slower)
Current Ratio
4.02
This Stock
vs
4.47
Sector Avg
-10.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
BEARISH | $835.41M | 8.96 | 12.9% | 13.6% | $18.18 | |
|
TLRY
Tilray Brands, Inc.
|
BEARISH | $833.32M | - | -63.2% | -156.7% | $7.15 | Compare |
|
MNKD
MannKind Corporation
|
BEARISH | $846.1M | 137.0 | -% | 1.7% | $2.74 | Compare |
|
SPRY
ARS Pharmaceuticals, Inc.
|
BEARISH | $812.25M | - | -92.3% | -203.3% | $8.18 | Compare |
|
TBPH
Theravance Biopharma, Inc.
|
NEUTRAL | $860.96M | 8.12 | 44.8% | 98.5% | $16.72 | Compare |
AMPH
Amphastar...
BEARISH
Mkt Cap
$835M
P/E
9.0
ROE
12.9%
Price
$18.18
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-09 | PETERS WILLIAM J | Chief Financial Officer | Stock Award | 58,693 | - |
| 2026-03-09 | ZHANG JACK YONGFENG | Chief Executive Officer | Stock Award | 252,966 | - |
| 2026-03-09 | ZHOU RONG | Officer | Stock Award | 39,432 | - |
| 2026-03-09 | LIAWATIDEWI YAKOB | Officer and Director | Stock Award | 35,450 | - |
| 2025-12-17 | ZHOU RONG | Officer | Option Exercise | 9,787 | $110,887 |
| 2025-12-17 | ZHOU RONG | Officer | Sale | 9,787 | $256,379 |
| 2025-12-12 | PETERSEN FLOYD F | Director | Sale | 4,163 | $107,508 |
| 2025-11-25 | PRINS RICHARD K | Director | Option Exercise | 4,179 | $69,748 |
| 2025-11-25 | PRINS RICHARD K | Director | Sale | 4,179 | $113,253 |
| 2025-11-13 | PETERSEN FLOYD F | Director | Option Exercise | 16,679 | $278,373 |
| 2025-11-13 | PETERSEN FLOYD F | Director | Sale | 16,679 | $441,837 |
| 2025-11-03 | PETERSEN FLOYD F | Director | Sale | 500 | $12,633 |
| 2025-10-01 | PETERSEN FLOYD F | Director | Sale | 500 | $13,602 |
PETERS WILLIAM J
Chief Financial Officer
2026-03-09
58,693 shares
ZHANG JACK YONGFENG
Chief Executive Officer
2026-03-09
252,966 shares
ZHOU RONG
Officer
2026-03-09
39,432 shares
LIAWATIDEWI YAKOB
Officer and Director
2026-03-09
35,450 shares
ZHOU RONG
Officer
2025-12-17
9,787 shares
·
$110,887
ZHOU RONG
Officer
2025-12-17
9,787 shares
·
$256,379
PETERSEN FLOYD F
Director
2025-12-12
4,163 shares
·
$107,508
PRINS RICHARD K
Director
2025-11-25
4,179 shares
·
$69,748
PRINS RICHARD K
Director
2025-11-25
4,179 shares
·
$113,253
PETERSEN FLOYD F
Director
2025-11-13
16,679 shares
·
$278,373
PETERSEN FLOYD F
Director
2025-11-13
16,679 shares
·
$441,837
PETERSEN FLOYD F
Director
2025-11-03
500 shares
·
$12,633
PETERSEN FLOYD F
Director
2025-10-01
500 shares
·
$13,602
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
7 analysts
Wells Fargo
2026-02-27
Overweight
Overweight
Needham
2026-02-27
Buy
Buy
Barclays
2025-12-09
Equal-Weight
Needham
2025-11-07
Buy
Buy
Needham
2025-10-22
Buy
Buy
Past News Coverage
Recent headlines mentioning AMPH from our newsroom.
Newest → oldest
No matching news yet.